vs
优尼威尔（DSGR）与Revvity（RVTY）财务数据对比。点击上方公司名可切换其他公司
Revvity的季度营收约是优尼威尔的1.5倍（$772.1M vs $518.0M），Revvity净利率更高（12.7% vs 1.2%，领先11.5%），优尼威尔同比增速更快（10.7% vs 5.9%），Revvity自由现金流更多（$161.8M vs $32.9M），过去两年优尼威尔的营收复合增速更高（13.1% vs 9.0%）
优尼威尔解决方案公司是一家全球化化学品与原料分销商，同时可为客户提供各类增值服务，业务网络覆盖全球多个地区，在化工及原料分销领域拥有丰富的行业经验与资源积累。
Revvity是一家美国生命科学与诊断领域企业，主要服务制药、生物技术行业客户，重点围绕细胞治疗、基因治疗等前沿技术领域提供相关产品与解决方案，其前身为业务布局多元的老牌企业珀金埃尔默。
DSGR vs RVTY — 直观对比
营收规模更大
RVTY
是对方的1.5倍
$518.0M
营收增速更快
DSGR
高出4.8%
5.9%
净利率更高
RVTY
高出11.5%
1.2%
自由现金流更多
RVTY
多$128.9M
$32.9M
两年增速更快
DSGR
近两年复合增速
9.0%
损益表 — Q3 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $518.0M | $772.1M |
| 净利润 | $6.5M | $98.4M |
| 毛利率 | 32.9% | — |
| 营业利润率 | 4.6% | 14.5% |
| 净利率 | 1.2% | 12.7% |
| 营收同比 | 10.7% | 5.9% |
| 净利润同比 | -70.6% | 3.9% |
| 每股收益（稀释后） | $0.14 | $0.86 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收DSGRRVTY
| Q4 25 | — | $772.1M | ||
| Q3 25 | $518.0M | $698.9M | ||
| Q2 25 | $502.4M | $720.3M | ||
| Q1 25 | $478.0M | $664.8M | ||
| Q4 24 | $480.5M | $729.4M | ||
| Q3 24 | $468.0M | $684.0M | ||
| Q2 24 | $439.5M | $691.7M | ||
| Q1 24 | $416.1M | $649.9M |
净利润DSGRRVTY
| Q4 25 | — | $98.4M | ||
| Q3 25 | $6.5M | $46.7M | ||
| Q2 25 | $5.0M | $53.9M | ||
| Q1 25 | $3.3M | $42.2M | ||
| Q4 24 | $-25.9M | $94.6M | ||
| Q3 24 | $21.9M | $94.4M | ||
| Q2 24 | $1.9M | $55.4M | ||
| Q1 24 | $-5.2M | $26.0M |
毛利率DSGRRVTY
| Q4 25 | — | — | ||
| Q3 25 | 32.9% | 53.6% | ||
| Q2 25 | 33.9% | 54.5% | ||
| Q1 25 | 34.3% | 56.5% | ||
| Q4 24 | 33.3% | — | ||
| Q3 24 | 33.9% | 56.3% | ||
| Q2 24 | 34.5% | 55.7% | ||
| Q1 24 | 34.5% | 54.6% |
营业利润率DSGRRVTY
| Q4 25 | — | 14.5% | ||
| Q3 25 | 4.6% | 11.7% | ||
| Q2 25 | 5.3% | 12.6% | ||
| Q1 25 | 4.2% | 10.9% | ||
| Q4 24 | 4.2% | 16.3% | ||
| Q3 24 | 4.0% | 14.3% | ||
| Q2 24 | 3.2% | 12.4% | ||
| Q1 24 | 0.7% | 6.8% |
净利率DSGRRVTY
| Q4 25 | — | 12.7% | ||
| Q3 25 | 1.2% | 6.7% | ||
| Q2 25 | 1.0% | 7.5% | ||
| Q1 25 | 0.7% | 6.4% | ||
| Q4 24 | -5.4% | 13.0% | ||
| Q3 24 | 4.7% | 13.8% | ||
| Q2 24 | 0.4% | 8.0% | ||
| Q1 24 | -1.3% | 4.0% |
每股收益（稀释后）DSGRRVTY
| Q4 25 | — | $0.86 | ||
| Q3 25 | $0.14 | $0.40 | ||
| Q2 25 | $0.11 | $0.46 | ||
| Q1 25 | $0.07 | $0.35 | ||
| Q4 24 | $-0.55 | $0.77 | ||
| Q3 24 | $0.46 | $0.77 | ||
| Q2 24 | $0.04 | $0.45 | ||
| Q1 24 | $-0.11 | $0.21 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $69.2M | $919.9M |
| 总债务越低越好 | $665.5M | — |
| 股东权益账面价值 | $653.9M | $7.3B |
| 总资产 | $1.8B | $12.2B |
| 负债/权益比越低杠杆越低 | 1.02× | — |
8季度趋势，按日历期对齐
现金及短期投资DSGRRVTY
| Q4 25 | — | $919.9M | ||
| Q3 25 | $69.2M | $931.4M | ||
| Q2 25 | $47.4M | $991.8M | ||
| Q1 25 | $65.4M | $1.1B | ||
| Q4 24 | $66.5M | $1.2B | ||
| Q3 24 | $61.3M | $1.2B | ||
| Q2 24 | $46.8M | $2.0B | ||
| Q1 24 | $73.1M | $1.7B |
总债务DSGRRVTY
| Q4 25 | — | — | ||
| Q3 25 | $665.5M | — | ||
| Q2 25 | $675.0M | — | ||
| Q1 25 | $712.4M | — | ||
| Q4 24 | $693.9M | — | ||
| Q3 24 | $704.1M | — | ||
| Q2 24 | $573.7M | — | ||
| Q1 24 | $535.7M | — |
股东权益DSGRRVTY
| Q4 25 | — | $7.3B | ||
| Q3 25 | $653.9M | $7.4B | ||
| Q2 25 | $649.4M | $7.6B | ||
| Q1 25 | $636.7M | $7.6B | ||
| Q4 24 | $640.5M | $7.7B | ||
| Q3 24 | $680.8M | $7.9B | ||
| Q2 24 | $653.3M | $7.9B | ||
| Q1 24 | $654.7M | $7.8B |
总资产DSGRRVTY
| Q4 25 | — | $12.2B | ||
| Q3 25 | $1.8B | $12.1B | ||
| Q2 25 | $1.8B | $12.4B | ||
| Q1 25 | $1.8B | $12.4B | ||
| Q4 24 | $1.7B | $12.4B | ||
| Q3 24 | $1.8B | $12.8B | ||
| Q2 24 | $1.6B | $13.4B | ||
| Q1 24 | $1.5B | $13.4B |
负债/权益比DSGRRVTY
| Q4 25 | — | — | ||
| Q3 25 | 1.02× | — | ||
| Q2 25 | 1.04× | — | ||
| Q1 25 | 1.12× | — | ||
| Q4 24 | 1.08× | — | ||
| Q3 24 | 1.03× | — | ||
| Q2 24 | 0.88× | — | ||
| Q1 24 | 0.82× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $38.4M | $182.0M |
| 自由现金流经营现金流 - 资本支出 | $32.9M | $161.8M |
| 自由现金流率自由现金流/营收 | 6.3% | 21.0% |
| 资本支出强度资本支出/营收 | 1.1% | 2.6% |
| 现金转化率经营现金流/净利润 | 5.95× | 1.85× |
| 过去12个月自由现金流最近4个季度 | $92.2M | $509.4M |
8季度趋势，按日历期对齐
经营现金流DSGRRVTY
| Q4 25 | — | $182.0M | ||
| Q3 25 | $38.4M | $138.5M | ||
| Q2 25 | $33.3M | $134.3M | ||
| Q1 25 | $-4.8M | $128.2M | ||
| Q4 24 | $45.7M | $174.2M | ||
| Q3 24 | $-17.3M | $147.9M | ||
| Q2 24 | $21.4M | $158.6M | ||
| Q1 24 | $6.6M | $147.6M |
自由现金流DSGRRVTY
| Q4 25 | — | $161.8M | ||
| Q3 25 | $32.9M | $120.0M | ||
| Q2 25 | $28.7M | $115.5M | ||
| Q1 25 | $-10.4M | $112.2M | ||
| Q4 24 | $41.1M | $149.8M | ||
| Q3 24 | $-20.5M | $125.6M | ||
| Q2 24 | $18.0M | $136.6M | ||
| Q1 24 | $4.2M | $129.7M |
自由现金流率DSGRRVTY
| Q4 25 | — | 21.0% | ||
| Q3 25 | 6.3% | 17.2% | ||
| Q2 25 | 5.7% | 16.0% | ||
| Q1 25 | -2.2% | 16.9% | ||
| Q4 24 | 8.6% | 20.5% | ||
| Q3 24 | -4.4% | 18.4% | ||
| Q2 24 | 4.1% | 19.7% | ||
| Q1 24 | 1.0% | 20.0% |
资本支出强度DSGRRVTY
| Q4 25 | — | 2.6% | ||
| Q3 25 | 1.1% | 2.6% | ||
| Q2 25 | 0.9% | 2.6% | ||
| Q1 25 | 1.2% | 2.4% | ||
| Q4 24 | 1.0% | 3.4% | ||
| Q3 24 | 0.7% | 3.3% | ||
| Q2 24 | 0.8% | 3.2% | ||
| Q1 24 | 0.6% | 2.7% |
现金转化率DSGRRVTY
| Q4 25 | — | 1.85× | ||
| Q3 25 | 5.95× | 2.97× | ||
| Q2 25 | 6.66× | 2.49× | ||
| Q1 25 | -1.46× | 3.03× | ||
| Q4 24 | — | 1.84× | ||
| Q3 24 | -0.79× | 1.57× | ||
| Q2 24 | 11.28× | 2.87× | ||
| Q1 24 | — | 5.67× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
DSGR
| Test Equity Segment | $206.5M | 40% |
| Gexpro Services Segment | $130.5M | 25% |
| Lawson Segment | $121.5M | 23% |
| Canada Branch Division Segment | $60.0M | 12% |
RVTY
| Immunodiagnostics | $240.8M | 31% |
| Life Sciences | $191.4M | 25% |
| Reproductive Health | $149.3M | 19% |
| Segment Operating Income | $132.0M | 17% |
| Software | $62.3M | 8% |
